english.prescrire.org > Spotlight > Archives : 2023 > The Drug Prescrire Awards for 2022: no "Pilule d'Or", one drug on the "Honours List". Details in the March issue of Prescrire International

Spotlight: Archives

Every month, the subjects in Prescrire’s Spotlight.

2023 : 1 | 30 | 60

The Drug Prescrire Awards for 2022: no "Pilule d'Or", one drug on the "Honours List". Details in the March issue of Prescrire International

Prescrire Awards None of the drugs examined by Prescrire in 2022 represented a major therapeutic advance worthy of a Pilule d'Or ("Golden Pill" Award). One drug made the Honours List, while one other was cited as Noteworthy.

Each month, the not-for-profit French journal Prescrire publishes systematic, independent analyses of the available evidence regarding new drugs, newly authorised indications for drugs already on the market, and new forms or new dose strengths of existing drugs.

The goal is to determine which of the multitude of new products or indications are useful additional treatment options, which should be used in place of other drugs, and which are to be avoided.

The annual Prescrire Awards recognise drugs, drug packaging and drug information singled out for attention by Prescrire's editorial staff. The Prescrire Awards for 2022 were announced in Paris on 1st February 2023.

 "Pilule d'Or" 

The "Pilule d'Or" ("Golden Pill") is awarded drugs that represent a major therapeutic advance in a particularly poorly served field.

  • No drugs examined in 2022 were a major therapeutic advance

Honours List

Drugs included on the Honours List constitute a clear advance for some patients compared with existing therapeutic options, albeit with limitations.

  • PAXLOVID° (nirmatrelvir + ritonavir) - Pfizer
     

Noteworthy

Drugs deemed "Noteworthy" provide a modest improvement in patient care.

  • ONUREG° (azacitidine) - Bristol-Myers Squibb

 

For details, see:
Le Palmarès Prescrire
> The Prescrire Awards for 2022
 

©Prescrire 1 March 2023

Source: "The Prescrire Awards" Prescrire International 2023; 32 (246): 80-81. Free.

Enjoy full access to Prescrire International, and support independent information

 
Share
Share on Facebook Share on Twitter


Read more:

All the subjects in
Prescrire's Spotlight
Free >